At Elanco, we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life.
We understand the powerful role healthy animals play in making lives better. As pets increasingly become important parts of our families, so too does the need to help them live longer, healthier, higher-quality lives. As the global population grows, so too will the need to meet the demand for safe, affordable food for all.
Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. We strive to develop and deliver products safe for consumers, animals and the environment through innovation and a shared vision to enrich the life of people worldwide.
Our Mission: We provide those who raise and care for animals with a comprehensive set of animal health products and knowledge services that empower them to address the global challenges of a diverse and changing world.
Our Vision: Food and Companionship Enriching Life
We are proud of our heritage of close customer relationships, scientific rigor and quality products, from the development of the first antibiotic for veterinary use in 1953 to today’s treatments that address the health needs of our pets. At the same time, we are humbled by the global challenges ahead and we will remain true to our heritage and our values to provide needed solutions in the field of animal health.
Elanco has helped shape the lives of animals and their human companions for more than half a century. Explore the timeline below to learn more.
Since 2008, Jeff Simmons has served as president of elanco, the animal health division of Eli Lilly and Company, (NYSE: LLY). As part of this role, he is also a senior vice president and executive officer of Lilly. Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. As a leading global animal health company, Elanco values innovation, both in scientific research and daily operations, and strives to cultivate a collaborative work environment for more than 6,500 employees worldwide through its vision of Food and Companionship Enriching Life.
In more than two decades with the company, Simmons has held a number of sales, marketing and management positions, in the United States and abroad, including serving as country director in Brazil and area director for West Europe based in the U.K.
These international experiences offered Simmons a new perspective on food and agriculture and created a deep conviction about the need for solutions to global food security. Elanco is bringing this vision to life via a commitment to end hunger for 100,000 families globally through a partnership with Heifer International, and begin breaking the cycle of hunger in 100 communities around the globe. Simmons has become an active advocate for the role technology plays in sustainable, efficient production of safe and affordable protein. He has published white papers on this topic, most recently, the ENOUGH report at www.ENOUGHmovement.com, and actively engages in food security discussions in social media on Twitter @JeffSimmons2050.
Simmons has held numerous leadership positions, including past board member of Chiquita Brands and former president of the International Federation of Animal Health (IFAH).
Ramiro Cabral currently serves as vice president and chief marketing officer, Elanco marketing and customer value. He has been responsible for Elanco business in Europe, Middle East and Africa. Prior to this, he held the position of area director for Western Europe. Since joining Elanco in 1998, Dr. Cabral has held a number of management positions within the company, including technical sales at Elanco Argentina, global marketing manager, beef business unit director in the U.S. Affiliate and affiliate director at Elanco Canada.
Dr. Cabral earned a DVM degree at UNICEN, Argentina in 1995 and an MBA from Purdue University in 2005. He joined Elanco after working some years in his family’s farm and working as a consultant in the Veterinary and Agribusiness industry.
Eric Graves is the president of North American Commercial Operations and is responsible for the company's U.S. and Canadian commercial business operations. Graves joined Elanco, the animal health division of Eli Lilly and Company in 2003 and has held a range of management roles and responsibilities.
Prior to his current role, he was vice president of Integration Planning for the Novartis Acquisition and led a complex, but successful integration over the last year. Previously, Graves was Elanco’s chief marketing officer and responsible for all aspects of marketing for existing and new products and brands. He led Elanco’s launch into the companion animal market, where he enjoyed being part of building a team and business that created growth and value for customers. Part of this time he was based in Europe, working on the global companion animal health business with additional emphasis on integrating a previous acquisition.
Prior to joining Elanco, Graves served as a director of veterinary marketing at Hill’s Pet Nutrition, Inc., a division of Colgate-Palmolive. He has also held a variety of positions in companion animal marketing, sales and operations at both Merial and Merck Agvet.
Ralph Heuser is the vice president of Europe, Middle East and Africa for Elanco Animal Health.
Prior to Elanco, Heuser had previously served as the region Head Europe for Novartis Animal Health. He first worked for Pfizer, starting in 1994, as regional key account manager, where he spent much time on the road and with customers. He says his company car became his office and the intense customer interaction greatly benefited him in later positions in sales, marketing and management.
Heuser then moved to become a farm animal business product manager for Boehringer in 1996 and later joined Novartis as head marketing and sales for the Human Medical Nutrition business (now part of Nestlé). During more than 18 years with Novartis and Novartis Animal Health he served in management positions for various countries in Central Europe as well as in Germany and Australia & New Zealand.He held the role as head of global sales excellence and was appointed Head of Region Europe in 2013.
Heuser studied agricultural economics at the University Bonn, Germany and received a doctorate in macroeconomics from the same university.
Jade Kas currently leads HR at Elanco. He joined Eli Lilly and Company in 1999 and spent his first four years in both sales and sales operations roles.
During the past 12 years, he has held a variety of roles in Human Resources supporting sales and marketing, global compensation, mergers and acquisitions, employee relations, and manufacturing.
In his spare time, Kas enjoys spending time with his family, volunteering to coach his kids sporting activities, strength training, and traveling with his family. Kas holds a bachelor's degree in Business Management & HR Management from IUPUI.
Lucas Montarce is the chief financial officer and vice president of Business Development, Strategy and Operations. Since joining Lilly in 2001, he has held a variety of positions across Latin America, Europe, and the U.S. including both local and regional CFO.
Born in Buenos Aires, Argentina, Montarce holds an undergraduate degree in business accounting from the Catholic University and a Masters of Business Administration from Universidad del CEMA.
Montarce currently serves in the board of Christel House a global children's charity, guiding the strategy for learning centers with the mission to transform the lives of impoverished children around the world building self-sufficient and contributing members to the society.
Julie Lawless is Sr. director of corporate affairs at Elanco, the animal health division of Eli Lilly and Company, (NYSE: LLY). In this role, she oversees global and regional communications, government affairs, corporate branding, cause & shared value and the Elanco Pulse Institute social listening center.
Lawless joined Elanco at the Greenfield, Indiana headquarters in 2014 as director of Corporate Communications. Under her leadership, the function has developed into a global capability with industry-leading corporate reputation initiatives.
She has a broad range of experiences in corporate affairs from several industries, including technology, automotive and food manufacturing. Most recently, Lawless worked in corporate communications, issues management and consumer relations at Mars, Incorporated, within the petcare segment. Before Mars, she spent several years at Nissan North America’s manufacturing plant and headquarters campus in Nashville, Tennessee in internal, regional, and product communications. She started her career as a field producer and reporter at KPLR-TV in St. Louis before moving to corporate public relations.
With a passion for pets, Lawless currently serves on the board for Elanco’s Companionship Cause, which focuses on service and therapy animals, as well as bringing the health benefits of pets to life.
Lawless currently serves as the communications chairperson for the Health for Animals organization representing the animal health sector.
Patrick Lenihan was appointed Elanco’s chief operating officer in March of 2017. Since joining Eli Lilly and Company (NYSE: LLY) in 2004, Lenihan has held various leadership roles in Six-Sigma, Human Resources, and Finance.
Lenihan has a track record of leading large, complex organizations and functions through change. Most recently, Lenihan had oversight of the financial and strategic operations for Lilly's Emerging Markets division, including responsibility for the division’s annual and strategic planning exercises. Prior to that he held leadership roles as the finance director of Lilly’s Insulin API manufacturing plants in Indianapolis and the director of Global Travel & Meetings for the company.
Lenihan earned his undergraduate degree in Management from the Krannert School of Management at Purdue University, magna cum laude, in 2000. He earned his M.B.A. in Finance, Marketing, and Biotechnology from the Kellogg School of Management at Northwestern University in 2008.
Patrick currently serves on the board of the Starfish Initiative and was formerly the chairman of the Board at Outreach Inc.
Elizabeth A. McGraw, currently serves as general counsel for Elanco Animal Health, a division of Eli Lilly and Company. McGraw leads a global team of legal professionals, with responsibilities for the legal affairs of Elanco around the world. Before assuming her current role, McGraw was the General Patent Counsel for Elanco for over five years, managing the global Intellectual Property portfolio for Elanco Animal Health, where she gained experience in product life-cycle planning, transactional work, and antitrust issues. Prior to joining Elanco, McGraw practiced as an in-house patent counsel for Eli Lilly and Company in Indianapolis for over 14 years, where she gained experience in global patent portfolio and exclusivity creation and managed the international patent litigation associated with gemcitabine. McGraw received her J.D. from the McKinney School of Law at Indiana University in 2002, and earned her B.S. in chemistry from Ball State University in 1993. McGraw is a native of Indiana and resides with her family in Indianapolis.
Michael Morgan, senior director of Ethics and Compliance is currently based at the Greenfield, Indiana headquarters.
Morgan has worked for Eli Lilly in the pharmaceutical industry for 30 years, including his current role in Elanco since September 2013. Prior to his current role, Morgan was the senior director of Ethics and Compliance for Europe, Canada and Australia from 2009-2013 and was director of Ethics and Compliance at the Lilly Corporate Headquarters and in the US affiliate in Indianapolis, from 2005 to 2009. Morgan has worked in a variety of other functions within Lilly including Sales/Sales Management, Marketing/Pricing, Health Economics/Health Outcomes and worked at PCS Health Systems in Disease Management.
He received his Bachelor of Science degree in Molecular and Cell Biology from Pennsylvania State University and his Master of Science in Business Management, Purdue University.
He holds certifications in Health Care Compliance Certification Seton Hall University Law School and Certified Compliance and Ethics Professional since 2009 from the Society of Corporate Compliance and Ethics.
Aaron Schacht is currently the Vice President for Global Research and Development.
Prior to this, Aaron Schacht held a role of global brand development leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as senior advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit.
Past roles included serving as executive director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as executive director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Schacht was co-founder, president and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up.
Previously, Schacht held roles as managing director of Lilly University, director of Knowledge Management, and manager of Strategy and Productivity for Discovery Research.
Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Dr. José Manuel Correia de Simas is currently responsible for Latin America Business. Simas joined Elanco in 2000 in Brazil where he held a technical role for cattle products. He moved to global marketing in a technical support role in 2002 and moved to the United States. In 2004, Simas took on the responsibility for the Argentina and Chile operations. In late 2005, he moved to Vienna, Austria to serve as area director for Elanco’s operations in Central-Eastern Europe/North Africa/Middle Eastern markets. Simas also led the U.S. beef business from 2008 to 2011. He has also lead B2B and Global Accounts and, prior to his actual position, has held Product Development, Regulatory and R&D operations.
Simas received a bachelor’s from the Federal University of Lavras in Brazil. He also holds a master’s and a doctorate in Animal Nutrition and Physiology from the University of Arizona, USA, as well as a post doctorate from the University of Sao Paulo, Brazil.
Dave Urbanek was promoted to vice president of Elanco Manufacturing in July 2017 after having served as vice president, Elanco Animal Health Manufacturing since February 2017. Urbanek joined the company in June 1988. Urbanek has broad experience in pharmaceutical manufacturing, in both drug product and bulk manufacturing, as well as, working closely with the Lilly business units. Before moving to Elanco, he most recently served as Lilly’s senior director, Emerging Markets Manufacturing. He has held the positions of senior director, Global Diabetes Manufacturing and senior director of the external drug products operations, including all Eli Lilly contract manufacturing operations and strategic alliances. Prior to those roles, Urbanek was the General Manager of Lilly’s Kinsale operations in Ireland and Speke operations in Liverpool, England. He also served as Site Head of the Indianapolis dry products plant, and Giessen operations in Germany. He received his Bachelor degree in Mechanical Engineering from the Rose-Hulman Institute of Technology and obtained his MBA in Business from Indiana University.
Jacques Zimmowitch is vice president of Global Quality.
Prior to this, Zimmowitch was vice president of Global Quality for Drug Product Operations for Americas and Asia and Global Computer System Operations for Eli Lilly and Company. In this capacity, he provided strategic direction and was responsible for Good Manufacturing Practices (GMP) compliance at the company’s Drug Product, Device and Distribution Operations in the Americas and Asia and for overall quality of the Lilly US Sales and Marketing affiliates. He also provided ultimate quality oversight for Consumer Product Quality Assurance (Complaints) programs globally and led the Parenteral Network Quality Steering Team, setting technical direction for quality and sterility assurance activities at these manufacturing sites. Zimmowitch was a member of Eli Lilly’s Manufacturing Policy Committee which is the governing body for Manufacturing and Supply Chain for Eli Lilly’s global manufacturing operations.
Zimmowitch joined Lilly initially in 1991and held multiple assignments in France and in the US through 2007 covering: Technical Services/Manufacturing Science, Quality Control Laboratory, Global Supply Chain, Operational Manufacturing and both Manufacturing Sites Quality Assurance and Global Quality Assurance. For two years, he led the Quality and Regulatory organization of Becton Dickinson, Pharmaceutical Systems business unit, before he rejoined Lilly in October 2009.
Zimmowitch was born and raised in France and holds a Master of Science (DEA Biology/Physiology) from France University of Paris and a Master of Business (Essec – France).
Jacques represented Eli Lilly and Company and the Pharmaceutical Industry as a member of the PhRMA GQMC (Global Quality and Manufacturing Committee).
Larbi Van Lier is the senior director and head of elanco asia pacific (APAC)
Larbi Van Lier has been with the company since 2001, when he joined the Novartis Belgium office as a product manager for Novartis’ Visioncare business. During the following years, he has held various roles in human and animal health including marketing manager, global marketing director, global category manager and country director for Spain and Portugal. Before becoming head of Elanco Asia Pacific, Van Lier served as head of the U.S. Beef and Swine Business unit, after serving as the country director for Elanco’s Italian animal health business.